Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-05-18 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
第五届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Yunnan Watson Biotechnology Co., Ltd. It details the meeting date, attendance, and specific decisions made regarding stock option price adjustments and share repurchase price limits. It includes voting results and references to legal opinions and independent directors' opinions. The content focuses on board decisions and management actions rather than financial results, audit opinions, or shareholder voting outcomes. The document length is short (1193 characters), and it is not a report or presentation but a formal announcement of board meeting resolutions. Therefore, it fits the category of Board/Management Information (MANG).
2023-05-18 Chinese
第五届监事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the ninth meeting of the fifth Supervisory Board of Yunnan Watson Biotechnology Co., Ltd. It details decisions on adjusting the exercise price of stock options and the upper limit of share repurchase price. The document includes voting results and references to related announcements on the official disclosure website. It does not contain financial statements or detailed financial data but rather reports on governance decisions and approvals by the supervisory board. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies. The document length is short (1234 characters), and it is not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2023-05-18 Chinese
北京国枫律师事务所关于公司2018年股票期权激励计划之调整行权价格事项的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the exercise price of a 2018 stock option incentive plan for a company. It details the legal basis, approval procedures, and specific adjustment calculations related to the stock option plan. The document is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to a capital/financing matter (stock option plan adjustment). It is not an announcement of voting results or a board/management change notice. Given the focus on stock option price adjustment, it fits best under Capital/Financing Update (CAP). The document length is 3223 characters, which is relatively short but contains substantive legal analysis and approval details, not just an announcement or certification. Therefore, the classification is CAP with high confidence.
2023-05-18 Chinese
关于调整回购股份价格上限的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company regarding the adjustment of the upper limit price for its share repurchase program. It details the board meeting decisions, the previous and adjusted price limits, the rationale for the adjustment based on dividend distribution, and the ongoing share repurchase plan. There are no financial statements or comprehensive financial data presented, nor is this a full report or earnings release. The content clearly relates to the company's buyback of its own shares and changes to the repurchase price limit. Therefore, this document fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on this topic, confirming it is not a full report or announcement of a report publication.
2023-05-18 Chinese
独立董事关于第五届董事会第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific board meeting matters, including adjustments to stock option exercise prices and share repurchase price limits. It references compliance with regulatory rules and company procedures but does not contain financial statements or detailed financial data. The content is focused on board/management decisions and approvals rather than a full report or announcement of voting results. The document length is short (964 characters), and it is a formal opinion related to board decisions. Therefore, it fits best under Board/Management Information (MANG).
2023-05-18 Chinese
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Implementation Announcement" for the year 2022 by Yunnan Watson Biotechnology Co., Ltd. It details the cash dividend distribution plan approved at the 2022 Annual General Meeting held on April 20, 2023, including dividend per share, total dividend amount, record date, ex-dividend date, and related adjustments to stock option exercise prices. The document explicitly states that the dividend plan was approved at the shareholders' meeting and provides detailed implementation information. The document length is 2666 characters, which is relatively short and focused solely on the dividend distribution implementation. It is not a full annual report or financial statement but an announcement of the implementation of the dividend distribution plan. Therefore, it fits best under the category of "Notice of Dividend Amount" (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2023-05-04 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.